Two competing technologies, haplo-identical transplantation and umbilical cord blood transplantation offer curative treatments for malignant and non-malignant hematologic conditions in patients who lack HLA-identical donors. The choice between the two approaches is mostly driven by comparison of long-term cure rates and frequency of complications. But short-term factors such as ease of implementation, procedural cost and duration of initial admission also affect centers' choices. Haplo-identical transplantation with post-transplant cyclophosphamide (PTCy-haplo) for graft versus host disease (GvHD) prophylaxis has garnered considerable interest.
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1,2 Most patients have haplo-identical family donors. The procedure is straightforward, can be readily implemented and engraftment is relatively fast compared to commonly used single or double umbilical cord blood (UCB) transplantation. Haplo-cord transplantation, the co-infusion of a cord blood graft with CD34-selected cells from a haploidentical related or unrelated donor obviates the prolonged pancytopenia and lengthy initial hospitalizations associated with UCB transplant. 3 But the CD34 selection of the haplo-graft and the purchase of a cord blood graft pose financial and technical barriers to implementation.
Kwon et al. 1 are the first to conduct a comparison of the outcomes of haplo-cord transplantation versus haplo-identical transplantation with post-transplant cyclophosphamide. They find similar long-term survival, progression-free survival, non-relapse mortality (NRM) and rates of disease progression. But the comparison is retrospective and the groups are unevenly poised with most imbalances favoring the PTCy-haplo cohort.
First, the cohorts were not contemporaneous: the 51 haplo-cord patients were transplanted over the course of 13 years (1999-2012) with a 'significant proportion' more than 10 years ago in the years 1999-2004 -an era when cord blood selection methods were not optimal. 4 Conversely, the PTCy-haplo transplants were performed between 2012 and 2014 and therefore have benefited from significant improvements in supportive care and rates of survival after allogeneic transplantation that have occurred over the decade. They also have less prolonged follow-up and thus are less at risk for late adverse events. Second, the PTCy-haplo cohort had more favorable disease characteristics. It included fewer patients transplanted beyond CR1 or with active disease, and there were significantly fewer patients with high/very high disease risk index (DRI) classifications. 5 Finally, a quarter of the haplo-cord cohort received TBI based conditioning, which in contrast to the Bu/Cy regimen that 100% of the PTCy-haplo cohort received has been shown to have worse NRM, relapse beyond 1 year, and lower leukemia-free and overall survival (OS). 6 Thus, three important metrics: the era of transplant, patient's disease characteristics and conditioning regimen favor the PTCy-haplo group. The only factor favoring the haplo-cord group was hematopoietic cell transplant-comorbidity index (HCT-CI). The fact that haplo-cord transplant, despite the more advanced patients, inferior conditioning regimens and prior era of transplant, held similar event free survival (EFS), OS, relapse, and NRM points to a potential advantage of haplo-cord transplant.
Some of the advantages are obvious from analysis of the secondary outcomes such as time to engraftment and incidence of GvHD. Haplo-cord transplant is associated with faster neutrophil engraftment (median 12 vs 17 days) compared to PTCy-haplo transplantation. The high doses of cyclophosphamide given as GvHD prophylaxis are myelosuppressive, and thus, delays in engraftment should not be surprising. Rates of GvHD were acceptable after either procedure, but were higher for acute GvHD (29 vs 9%) and chronic GvHD (38 vs 20%) after PTCy-haplo transplantation. Both acute and chronic GvHD are serious complications that will affect long-term health and survival and -despite associated graft versus leukemia (GVL) effects-will over time adversely affect survival. 7 Other complications, such as CMV reactivation or hemorrhagic cystitis were also increased after PTCy-haplo transplant. 8, 9 Having similar rates of recurrence and similar long-term survival in a group of patients with worse DRI suggests a more powerful GVL effect from the cord blood graft. This is consistent with multiple lines of evidence. In the setting of minimal residual disease, Milano et al. 10 suggest that cord blood transplantation lowers rates of relapse. Our group also noted reduced rates of relapse associated with higher cord blood donor chimerism, similarly suggesting that cord engraftment mediates disease control. 11 Drawing from parallel multi-center Phase 2 trials, Brunstein et al. 12 reported outcomes of double unit cord blood transplantation and unmanipulated haplo-marrow transplantation with reduce-intensity conditioning. The 1-year NRM and relapse rates were 24% and 31% in the double UCB transplantation trial, respectively, and 7 and 45%, respectively, in the haplo-marrow trial. Finally, in a murine lymphoma model, cord blood grafts had vastly superior graft versus tumor effect. 13 Conversely large European registry analysis comparing single or double UCBT to unmanipulated haplo-identical transplant, rates of relapse were similar, although rates of chronic GvHD were lower with UCB transplantation. 14 What about costs? The graft procurement and preparation costs undoubtedly favor haplo-identical transplants. But other important cost drivers, including duration of neutropeniaassociated with initial length of stay after myeloablative conditioning, incidence of acute and of chronic GvHD all favored haplo-cord transplantation and the relative overall long-term cost impact of either procedure will therefore require further study.
Finally, in our experience in a large multi-ethnic metropolitan area, up to 25% of adults lack readily available haplo-identical donors and therefore do not qualify for haplo-identical transplantation. In nearly all such cases, one can however readily substitute a partially matched unrelated registry donor in the haplo-cord procedure. 16 PTCy-haplo has rapidly become established as a simple and relatively effective method for inducing post-transplant tolerance with acceptable rates of engraftment and GvHD. However, haplo-cord blood transplantation-despite increased graft procurement costs and complexity-remains a viable option that has been reported to be superior to double UCB transplantation, 17 and may well be superior to PTCy-haplo in terms of access, rate of engraftment, incidence of acute and chronic GvHD and long-term disease control. Further studies comparing these options directly are needed.
